By Maria Armental
Biogen Inc.'s investors will receive a special dividend, completing the planned spinoff of its hemophilia drug business.
Cambridge, Mass.-based Biogen moved to separate the business, about 5% of Biogen's $10.76 billion in annual revenue, to focus on neurology drugs.
Under the plan, approved Tuesday by Biogen's board, Biogen investors as of the close of business on Jan. 17 will receive a share in Bioverativ Inc., the standalone hemophilia company, for each two shares they hold in Biogen. The dividend would be paid on Feb. 1.
Biogen will retain no ownership interest.
Bioverativ, which has applied to trade on Nasdaq under the ticker symbol BIVV, had about $631.2 million in revenue for the first nine months of the year, largely from sales of the hemophilia drugs Eloctate and Alprolix, according to a regulatory filing.
Biogen's stock, down 7% this year, was down 0.22% 18 cents to $285.59 in recent after-hours trading.
Write to Maria Armental at firstname.lastname@example.org
(END) Dow Jones Newswires
December 20, 2016 17:10 ET (22:10 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.